Developing RNA-based cancer immunotherapies
Cancer remains a major global health burden and a leading cause of death worldwide. New therapeutic strategies are urgently needed that can overcome diverse mechanisms of resistance across cancer types.
This project aims to establish a flexible platform for developing RNA-based immunotherapies for difficult-to-treat cancers.
Key details
- 20268601
- PhD
- Applications close on 31 October 2026
- Domestic, International
- Medicine and health
- $40,900 p.a.
Rather than targeting a single tumour type or antigen, the approach combines two fundamental requirements for effective anti-tumour immunity:
- precise recognition of cancer-specific antigens
- stimulation of the immune system to generate and sustain a functional response.
RNA technology provides a modular framework in which these components can be readily adapted as new tumour antigens, immune-stimulatory molecules and delivery strategies are identified.
Successful development of this platform will provide proof-of-concept for a transferable therapeutic framework that can be tailored to cancers with distinct antigens and immune microenvironments, including tumours that respond poorly to existing immunotherapies.
In the longer term, this work could accelerate development of next-generation RNA cancer immunotherapies and provide new treatment options for patients whose cancers remain poorly served by current therapies, ultimately improving clinical outcomes and quality of life.
Availability
This scholarship is available to eligible candidates to undertake a direct entry three-year PhD program.
Components
The scholarship comprises:
- a tuition fee offset
- a living allowance stipend.
The value of each stipend scholarship is $40,900 per annum (full time, indexed) for three years.
How to apply
Before submitting your application, submit an expression of interest to Professor Helen Rizos at helen.rizos@mq.edu.au.